DUSP14 attenuates airway inflammation and mucus hypersecretion in allergic asthma by regulating TAK1 activity

Rui Kong1, Jun Bai2, Qing Yao3

  • 1Department of Rheumatology and Allergy, Xuanwu Hospital, Capital Medical University, Beijing, China.

Immunology Letters
|May 31, 2025
PubMed

Insights

Dual-specificity phosphatase 14 (DUSP14) alleviates allergic asthma by inhibiting the TAK1 and NF-κB pathway. This study reveals DUSP14 as a potential therapeutic target for reducing airway inflammation and mucus production in asthma.

Area of Science:

  • Immunology
  • Molecular Biology
  • Respiratory Medicine

Background:

  • Allergic asthma involves chronic airway inflammation, mucus hypersecretion, and hyperresponsiveness.
  • Dual-specificity phosphatase 14 (DUSP14) regulates biological processes, but its role in asthma is unclear.

Purpose of the Study:

  • To investigate the function and mechanism of DUSP14 in asthma-related airway inflammation.
  • To explore DUSP14 as a potential therapeutic target for allergic asthma.

Main Methods:

  • Ovalbumin (OVA)-induced asthma mouse model.
  • In vitro studies using bronchial epithelial cells (BEAS-2B).
  • Co-immunoprecipitation assay to identify protein interactions.

Main Results:

  • DUSP14 levels were diminished in an OVA-induced asthma model.
  • DUSP14 overexpression reduced airway inflammation and mucus production in vivo and in vitro.
  • DUSP14 interacted with TAK1, inhibiting TAK1 and NF-κB signaling pathway activation.

Conclusions:

  • DUSP14 alleviates allergic asthma by inhibiting the TAK1-NF-κB signaling pathway.
  • The DUSP14-TAK1-NF-κB axis represents a promising therapeutic target for allergic asthma.

Related Concept Videos

Asthma: Pathogenesis and Management01:20

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.
623
Antiasthma Drugs: Leukotriene Modifiers01:19

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
505
Asthma-II: Pathophysiology and Classification01:26

Asthma-II: Pathophysiology and Classification

Asthma is a prevalent chronic respiratory condition marked by inflammation and hyperresponsiveness of the airways. Its pathophysiology involves complex interactions among inflammatory pathways, immune responses, and neural mechanisms.
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
2.9K
Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs01:25

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...
490
Asthma-I: Introduction01:29

Asthma-I: Introduction

Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
2.8K
Antiasthma Drugs: Muscarinic Receptor Antagonists01:20

Antiasthma Drugs: Muscarinic Receptor Antagonists

Muscarinic receptor antagonists, also known as antimuscarinic agents, are a class of bronchodilators used to treat asthma, although they are more commonly used to treat COPD. They work by inhibiting the action of acetylcholine (ACh), a neurotransmitter, on muscarinic receptors found in the airways.
Antimuscarinic agents compete with ACh for the same binding site on the muscarinic receptors. By binding to these receptors, they inhibit the downstream effects of ACh and block the parasympathetic...
479